NEW YORK, March 4, 2011 /PRNewswire/ -- NeoStem, Inc. (NYSE Amex: NBS), an international biopharmaceutical company with operations in the U.S. and China, announced today that NeoStem will present on a panel at the 31st Annual Cowen Group Health Care Conference. The panel discussion will take place on Monday, March 7, 2011 at 1 PM and Dr. Robin Smith, the Company's Chairman and CEO, will present on Tuesday, March 8, 2011 at 10:15 AM. The Conference will be held at the Boston Marriott Copley Place in Boston, Massachusetts.
The panel will be focused on China which will give NeoStem a platform to discuss its China strategy and highlight recent developments related to China expansion activities. Additionally, the company will discuss why management believes the recent acquisition of Progenitor Cell Therapy, LLC ("PCT") positions the Company to become a leader in cell-based medicine. PCT is an internationally recognized cell therapy services and development company that, through its cGMP certified manufacturing facilities and team of professionals, facilitates the preclinical and clinical development and commercialization of cellular therapies for clients in the United States and internationally. The Company is well positioned to capture the paradigm shift to cell-based medicine.
The Company will discuss future plans such as the launch of a new service by bundling together adult stem cell banking and cord blood banking into a multi-generational stem cell collection and storage plan that the Company will call the "Family Plan" with well-recognized television and online healthcare professional, Dr. Manny Alvarez.
Additionally, the Company will discuss its cell-based therapeutics development strategy in the US and China to articulate near and long term goals and identify where the value inflection points exist.
Dr. Robin Smith said, "It is an exciting time for NeoStem as we add service lines to our business, grow product revenues, advance our therapeutics development strategy and add seasoned management to assist in the execution of our plan."
About NeoStem, Inc.NeoStem, Inc. is an international biopharmaceutical company with adult stem cell operations in the U.S., a network of adult stem cell therapeutic providers in China as well as a 51% ownership interest in a profitable Chinese generic pharmaceutical manufacturing company. NeoStem is focused on accelerating the development of proprietary cellular therapies and becoming a single source for collection, storage, manufacturing, therapeutic development and transportation of cells for cell based medicine and regenerative science globally. The Company also has licensed various cellular therapy technologies, including worldwide exclusive licenses to a wound healing technology and to VSEL™ Technology which uses very small embryonic-like stem cells, which are adult stem cells that have been shown to have several physical characteristics that are generally found in embryonic stem cells.
For more information, please visit: http://www.neostem.com.
About Cowen Group, Inc.Cowen Group, Inc. is a leading diversified financial services firm providing alternative investment management, investment banking, research, and sales and trading services through its business units, Ramius and Cowen and Company. Its alternative investment management products include hedge funds, fund of funds, real estate funds, healthcare royalty funds, cash management and commodity trading funds, offered primarily under the Ramius name. Cowen and Company offers industry focused investment banking for growth-oriented companies, domain knowledge-driven research and a sales and trading platform for institutional investors. Founded in 1918, the firm is headquartered in New York and has offices located in major financial centers around the world.
Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward looking statements include statements herein with respect to the ability of PCT's business to complement NeoStem's adult stem cell operations and successful execution of the Company's strategy, as well as other advances in the Company's business, about which no assurances can be given. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 31, 2010, its Form S-4/A filed with the Securities and Exchange Commission on December 3, 2010 as well as other periodic filings made with the Securities and Exchange Commission. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control. NeoStem may experience difficulties in integrating PCT's business and could fail to realize potential benefits of the merger. Acquisitions may entail numerous risks for NeoStem, including difficulties in assimilating acquired operations, technologies or products, including the loss of key employees from acquired businesses.For more information, please contact:NeoStem, Inc.Robin Smith, CEOPhone: +1-212-584-4174Email: firstname.lastname@example.org Web: http://www.neostem.com
|SOURCE NeoStem, Inc.|
Copyright©2010 PR Newswire.
All rights reserved